ENDRA Life Sciences Inc.
NDRA Healthcare Diagnostics & Research
In the quarter to June 2026, EPS grew 107.0% and free cash flow grew 15.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow NDRA
ENDRA Life Sciences Inc. (NDRA) EV/Sales
As of 16 October 2026, ENDRA Life Sciences Inc. (NDRA) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from −17.4× (September 2024) to 248× (April 2021); the current reading is higher than 20% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2018 | −3.4× | — |
| FY2017 | 13.5× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2018 | 17.0× | 25.97% |
| Dec 2017 | 13.5× | — |
| Sep 2017 | 0.0× | — |
| Jun 2017 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.1× |
| BIAF bioAffinity Technologies, Inc. compare | −0.1× |
| XWEL XWELL, Inc. compare | 0.0× |
| ADVB Advanced Biomed Inc. compare | n/m |
| PMD Psychemedics Corporation compare | 0.7× |
| NOTVQ Inotiv, Inc. compare | 1.6× |
| NDRA ENDRA Life Sciences Inc. | 2.2× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)